Drugs / Teniposide

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) VUMON 1992-07-14 fda.gov

Trials 17 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00004916 Feb 1999 → Oct 2002 lymphoma Northwestern University Completed No outcome recorded
Phase 27 trials
Phase 2 NCT06758700 Feb 2025 → Jun 2026 overdue small cell lung carcinoma Shanghai Pulmonary Hospital, Shanghai, China Recruiting No outcome recorded
Phase 2 NCT07188441 Aug 2024 → Dec 2026 expected central nervous system germ cell tumor Chengcheng Guo Recruiting No outcome recorded
Phase 2 NCT07583511 Feb 2024 → May 2027 expected small cell lung carcinoma Sun Yat-sen University Recruiting No outcome recorded
Phase 2 NCT02788201 Mar 2017 → Oct 2019 urinary bladder cancer, urothelial carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00186875 Nov 2003 → Aug 2016 acute lymphoblastic leukemia, lymphoblastic lymphoma St. Jude Children's Research Hospital Completed No outcome recorded
Phase 2 NCT00004231 Oct 1999 → Aug 2006 lymphoma Northwestern University Completed No outcome recorded
Phase 2 NCT00002531 Jan 1993 → ? leukemia Johann Wolfgang Goethe University Hospital Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT07185373 Oct 2025 → Sep 2028 expected primary central nervous system lymphoma Huashan Hospital Not yet recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT06038422 Sep 2023 → Sep 2024 hemophagocytic syndrome, refractory malignant neoplasm Beijing Friendship Hospital Unknown No outcome recorded
Phase 45 trials
Phase 4 NCT01960192 Jun 2012 → Jun 2016 primary central nervous system lymphoma Mingzhi Zhang Unknown No outcome recorded
Phase 4 NCT00853008 Jan 2003 → Nov 2012 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00199056 Oct 1999 → Nov 2003 adult acute lymphoblastic leukemia Goethe University Completed No outcome recorded
Phase 4 NCT00199095 Feb 1997 → Jun 2003 adult acute lymphoblastic leukemia Goethe University Completed No outcome recorded
Phase 4 NCT00199069 Apr 1993 → Jan 1999 adult acute lymphoblastic leukemia Goethe University Completed No outcome recorded
Phase not applicable2 trials
NCT07074470 Jan 2025 → Jan 2030 expected primary central nervous system lymphoma The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
NCT06048107 Oct 2023 → Sep 2024 hemophagocytic syndrome Beijing Friendship Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 8 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 24 trials
Phase 2 NCT01700946 Comparator Apr 2013 → Jul 2021 B-cell childhood acute lymphoblastic leukemia St. Jude Children's Research Hospital Completed No outcome recorded
Phase 2 NCT01430013 Background Jun 2011 → Nov 2015 T-cell non-Hodgkin lymphoma Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 2 NCT00184041 Background Jul 2004 → Dec 2011 adult acute lymphoblastic leukemia University of Southern California Completed No outcome recorded
Phase 2 NCT01290120 Background Nov 2002 → Jun 2014 Burkitt lymphoma Northern Italy Leukemia Group Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00187083 Background Feb 1997 → Dec 2003 acute lymphoblastic leukemia St. Jude Children's Research Hospital Completed No outcome recorded
Phase 42 trials
Phase 4 NCT00199004 Background Apr 2004 → Mar 2009 adult acute lymphoblastic leukemia Johann Wolfgang Goethe University Hospital Completed No outcome recorded
Phase 4 NCT00198991 Background Apr 2003 → Jun 2011 adult acute lymphoblastic leukemia Goethe University Completed No outcome recorded
Phase not applicable1 trial
NCT00343369 Background Jan 2003 → ? leukemia University Medical Center Hamburg-Eppendorf Unknown No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 26 sources stand behind the page.

FieldValueCited text
Known as teniposide “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120
19

“Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)” NCT06038422

“Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone” NCT01430013

“FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt” NCT01960192

“Temsirolimus, Teniposide, Thioguanine” NCT02788201

NCT00002531

NCT00004916

NCT07188441

NCT07583511

NCT01700946

NCT00853008

NCT00187083

NCT00198991

NCT06048107

NCT00343369

NCT06758700

NCT00186875

NCT07185373

NCT07074470

NCT00004231

Known as NSC-122819 ChEMBL registry synonym — accepted as the source's own label CHEMBL452231
Known as Teniposido ChEMBL registry synonym — accepted as the source's own label CHEMBL452231
Known as VM-26 “teniposide (VM-26) IV over 1 hour” NCT00002531
5

NCT00199004

NCT00184041

NCT00199056

NCT00199069

NCT00199095

Known as Vumon ChEMBL registry synonym — accepted as the source's own label CHEMBL452231
Modality Small molecule CHEMBL452231
Route Intravenous “teniposide (VM-26) IV over 1 hour” NCT00002531